By: Dr. Shipra Kunwar, Consultant – Obstetrician and Gynecologist, Manipal Hospital, Kharadi, Pune
One of the most common viral infections in the world, the human papillomavirus (HPV) is a major contributor to several malignancies, including vaginal, cervical, anal, and throat cancers. Although HPV infection often goes ignored, it can have serious long-term effects. One of the most successful preventative measures in contemporary medicine is the HPV vaccination, which works best when given at a young age.
Close skin-to-skin contact, particularly during sexual activity, is the main way that HPV is spread. Infection often happens shortly after exposure, usually in adolescence or the early stages of adulthood. Once within the body, the virus can continue to cause cellular alterations that might eventually lead to cancer for years without showing any signs. The only way to cure HPV is to manage its consequences; medications cannot eradicate the virus itself. As such, prevention becomes the most effective tactic.
The HPV vaccine is designed to prevent infection by the most high-risk HPV strains responsible for the majority of HPV-related cancers. Scientific evidence consistently shows that the immune response generated by the vaccine is strongest when given before exposure to the virus. This is why early vaccination—typically recommended in pre-adolescents and adolescents—is crucial.
From a biological standpoint, younger immune systems respond more robustly to vaccines. When administered at an early age, the HPV vaccine produces higher antibody levels, offering longer-lasting and more effective protection. Once HPV exposure has already occurred, the vaccine cannot reverse existing infection or virus-related cell damage. Early vaccination ensures protection is established well before any potential exposure.
The vaccine is given as a series of injections, depending on the age at initiation. In younger adolescents, fewer doses are often sufficient, while older individuals may require additional doses to achieve adequate immunity. The procedure itself is simple, safe, and does not involve surgery or hospital admission.
By preventing HPV infection at the outset, the vaccine significantly reduces the future risk of cervical cancer and other HPV-associated malignancies. This has a profound public health impact, lowering the burden of cancer screening, complex surgeries, chemotherapy, and radiation treatments later in life.
HPV vaccination is not limited to girls alone. Vaccinating boys also plays a critical role in preventing HPV-related cancers and in reducing overall virus transmission within the community.
Early HPV vaccination represents a shift from cancer treatment to cancer prevention. Given at the right time, it offers long-term protection, reduces future disease burden, and saves lives. In the fight against HPV-related cancers, timing is not just important—it is decisive
